Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

674 - Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma for general condition patients: a single institution experience from Thailand


20 Dec 2015


Poster presentation 2


Ekkasit Tharavichitkul


Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525


E. Tharavichitkul, S. Chakrabandhu, P. Klunklin, W. Onchan, B. Supawongwattana, N. Pukanhaphan, R.M. Galalae, I. Chitapanarux

Author affiliations

  • The Division Of Therapeutic Radiology And Oncology, Chiang Mai University, 50200 - Chiang Mai/TH


Abstract 674


To report the results of concurrent chemo-radiation with cisplatin versus carboplatin in locally advanced cervical carcinoma.


From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging, were prospectively assigned to be treated with weekly cisplatin versus weekly carboplatin combined with radical radiotherapy. All patients were aged between 18-70 years at study entry, had a good performance status and normal laboratory functions. Treatment outcomes and toxicities were evaluated.


Two-hundred and thirteen patients could be evaluated. At the median follow-up time of 43 months (Interquartile range; 23.5-57 months), the local control, disease-free survival, metastasis-free survival and overall survival rates were 93%, 80.8%, 85.0% and 87.3%, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty six percents of the patients in the carboplatin group received more than 4 cycles, while there were only 72% in the cisplatin group who completed more than 4 cycles (p = 0.02). In terms of acute toxicity, cisplatin caused significantly more anemia (p = 0.026), neutropenia (p = 0.044) and nephrotoxicity (p = 0.031) than carboplatin. No difference in late toxicity was observed in this study.


Carboplatin yielded comparable results to cisplatin in concurrent chemo-radiation for locally advanced cervical cancer. In addition, carboplatin was associated with a higher compliance rate and had significantly lower incidence of anemia, neutropenia and nephrotoxicity.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings